GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Exicure Inc.
Shares of Exicure, a biotech company, have collapsed following clinical trial failures. The current price chart reflects the company's efforts to find new applications for its technology and survive, which poses very high risks for investors.
Share prices of companies in the market segment - Dna
Exicure is an early-stage biotech company developing spherical nucleic acid-based drugs for the treatment of neurological and other diseases. We classified it as a "DNA" company. The chart below highlights the high risks associated with companies undergoing restructuring.
Broad Market Index - GURU.Markets
Exicure is a biotech company developing spherical nucleic acid-based drugs for the treatment of neurological and other diseases. Its innovative platform makes it part of the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
XCUR - Daily change in the company's share price Exicure Inc.
Exicure, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies, especially after restructuring. This metric is a measure of its sensitivity to news about its RNA technologies.
Daily change in the price of a set of shares in a market segment - Dna
Exicure, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with XCUR's performance, with its gene therapy platform, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Exicure is a biotech company developing therapeutics based on spherical nucleic acids. The company's shares are a bet on a breakthrough in gene therapy. Their high, speculative volatility is part of the dynamic of the innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Exicure Inc.
Exicure, Inc.'s year-over-year performance tells the story of its struggle to survive after the failure of its core program. Its 12-month market cap reflects its status as a company seeking strategic alternatives. Its valuation is essentially the value of its remaining cash and technology, which could be sold or used in a new project.
Annual dynamics of market capitalization of the market segment - Dna
Exicure, Inc. is an early-stage biotech company. Its stock performance is entirely dependent on the results of preclinical and clinical trials. The chart reflects the high risks and speculative nature typical of this sector, where a single success or failure can dramatically change the valuation.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Exicure is a very small and highly speculative biotech company. Its stock price has nothing to do with fundamentals or the economy, but is driven by news of trials and investor confidence in the potential of its developments, making it a high-risk bet on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Exicure Inc.
Exicure is a biotech company undergoing restructuring. Its monthly performance reflects not so much scientific progress as corporate actions and efforts to preserve shareholder value. News of asset sales or mergers are key.
Monthly dynamics of market capitalization of the market segment - Dna
This chart reflects the dynamics of the volatile biotech sector. For Exicure, a company undergoing restructuring, it's the backdrop. Its movements reflect not scientific breakthroughs, but corporate actions and attempts to find a new development strategy.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Exicure is an early-stage biotech developing therapeutics based on spherical nucleic acids. Following clinical failures, the company is undergoing a restructuring. The overall market chart is irrelevant; Exicure shares are driven by news about the company's survival, not by overall trends, and are highly speculative.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Exicure Inc.
Exicure, a biotech company undergoing a major restructuring following research setbacks, is experiencing extremely high volatility. The stock's weekly performance reflects speculative reactions to any news about the future of its spherical nucleic acid (SNA) technology and efforts to find strategic alternatives.
Weekly dynamics of market capitalization of the market segment - Dna
Exicure operates in the biotech sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire sector, while failure can dampen investor interest. The chart will show whether XCUR is following the general speculation or whether its restructuring is creating its own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a biotech company, Exicure often defies broader market trends. Its fate depends not on GDP or inflation, but on news about its restructuring and the future of its technology. The chart below clearly demonstrates how XCUR shares can live a life of their own, separate from the broader market.
Market capitalization of the company, segment and market as a whole
XCUR - Market capitalization of the company Exicure Inc.
Exicure's chart is a story of high hopes and devastating setbacks in RNA therapeutics. This biotech's market cap reflects its struggle to survive after the failure of key research. Its rock-bottom valuation is a market verdict, demonstrating how difficult it is to restore confidence after scientific setbacks.
XCUR - Share of the company's market capitalization Exicure Inc. within the market segment - Dna
Exicure is a biotech company developing drugs based on its spherical nucleic acid (SNA) platform. Its market share reflects its current status following clinical failures. The chart shows the company's history as it seeks strategic alternatives for its innovative technology.
Market capitalization of the market segment - Dna
Exicure develops spherical nucleic acid (SNA)-based gene therapy products. The chart below shows the market capitalization of the DNA technology sector. This represents the valuation of one of the most advanced platforms, which could open up new possibilities for treating genetic diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Exicure is an early-stage biotech company developing therapeutics based on spherical nucleic acids. Its market capitalization reflects the risks and potential of its scientific platform. The chart below shows the economic weight of companies working with advanced technologies.
Book value capitalization of the company, segment and market as a whole
XCUR - Book value capitalization of the company Exicure Inc.
Exicure's book value is its scientific platform and remaining capital. The company's foundation consists of its patents for spherical nucleic acid (SNA) technology and cash flow after the termination of most clinical development. The chart below shows the financial base on which the company is exploring new avenues for applying its unique technology.
XCUR - Share of the company's book capitalization Exicure Inc. within the market segment - Dna
Exicure, Inc., a biopharmaceutical company, is focused on R&D. Its laboratories are its primary physical asset. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for a company in the research stage.
Market segment balance sheet capitalization - Dna
Exicure is an early-stage biotech company working with spherical nucleic acid technology. Its value is derived almost entirely from its intellectual property. A book value chart will demonstrate how intangible its business is, awaiting scientific breakthroughs.
Book value of all companies included in the broad market index - GURU.Markets
Exicure's book value is a scientific platform based on spherical nucleic acids (SNAs). The company's assets are its laboratories, intellectual property, and capital remaining for the exploration of strategic alternatives. This is the material basis for a unique technology that is seeking new applications after clinical trials failed.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Exicure Inc.
Exicure is a biotech company developing therapeutics based on spherical nucleic acids. Its book value is primarily cash. Its market capitalization reflects the market's (often skeptical) assessment of the potential of its scientific platform after previous research failures.
Market to book capitalization ratio in a market segment - Dna
Exicure is a biotech company facing challenges in developing its nucleic acid-based platform. The chart will likely show a market value near or below book value, reflecting investor sentiment about the company's risks and future.
Market to book capitalization ratio for the market as a whole
Exicure is a biotech company developing drugs based on spherical nucleic acids. After research setbacks, the company is exploring new avenues. The chart shows how the market values a company whose core technology has failed to live up to expectations, and whose value is now close to its balance sheet value.
Debts of the company, segment and market as a whole
XCUR - Company debts Exicure Inc.
Exicure, a biotech company undergoing restructuring, is using its remaining debt to maintain minimal operating activity. This schedule likely reflects the company's efforts to preserve its scientific platform and intellectual property in anticipation of a potential partnership or asset sale.
Market segment debts - Dna
Exicure is a biotech company that suffered serious setbacks in clinical trials and was forced to drastically reduce its operations and staff. Its financial position reflects this crisis. This chart shows its remaining capital and liabilities and illustrates the risks of early-stage biotech investing.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Exicure Inc.
Exicure is a biotech company working in DNA-based gene therapy. This chart reflects its reliance on debt financing. For a company at the cutting edge of science, where R&D costs are enormous and results are uncertain, any debt creates enormous pressure and is a key factor in investment risk.
Market segment debt to market segment book capitalization - Dna
Exicure, Inc. is a clinical-stage biotech company working in gene therapy. This chart for the biotech sector illustrates how the industry as a whole raises capital to fund lengthy and expensive research. It provides context for assessing the financial viability of a company that does not yet have commercial products.
Debt to book value of all companies in the market
Exicure develops drugs based on spherical nucleic acid technology to treat genetic diseases. Biotechnology requires massive investment. The chart showing the overall debt-to-book value ratio of the market demonstrates how willing investors are to finance breakthrough but risky scientific platforms, which determines Exicure's future.
P/E of the company, segment and market as a whole
P/E - Exicure Inc.
Exicure is an early-stage biotech developing therapeutics based on spherical nucleic acids. This chart reflects the high risks and potential of its technology. Its dynamics show how investors assess the platform's scientific prospects after past failures and how confident they are in its potential for future success.
P/E of the market segment - Dna
Exicure, Inc. is an early-stage biotech company. This chart shows the average P/E for the biotech sector. Comparing a company's P/E to this benchmark provides insight into how the market values its technology platform after past challenges—whether it's giving it another chance, valuing it above or below the industry average.
P/E of the market as a whole
Exicure is a biotech company that has faced significant challenges following clinical trial failures for its spherical nucleic acid platform. Its future is uncertain. This chart shows the sentiment in the biotech sector. The company's valuation reflects a high degree of risk and exemplifies how quickly the outlook in biotech can change following negative news.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Exicure Inc.
Exicure is an early-stage biotech developing therapeutics based on spherical nucleic acids. Following research setbacks, the company is undergoing a restructuring. The timeline reflects high uncertainty. The market is assessing whether the remaining technology has any future potential.
%20P%2FE%20Exicure%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Exicure-Inc.&v=1772646484645 "Chart of the company's future (projected) P/E Exicure Inc.")
Future (projected) P/E of the market segment - Dna
Exicure is an early-stage biotech developing therapeutics based on spherical nucleic acids. This chart shows how its future revenue expectations compare to the industry average, reflecting the high risk and potential reward associated with its breakthrough, yet unproven, technology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772646484650 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Exicure is an early-stage biotech company developing therapeutics based on spherical nucleic acids. Following research failures, the company is seeking strategic alternatives. Its value is based on the option to potentially restart operations or sell its technology, not on market expectations.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772646484655 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Exicure Inc.
Exicure, Inc. is an early-stage biotechnology company developing spherical nucleic acid (SNA)-based therapeutics for the treatment of neurological and other diseases. Its financial metrics reflect research and development expenditures. This chart illustrates the financial investments required to advance its innovative scientific platform.
Profit of companies in the market segment - Dna
Exicure, Inc. is an early-stage biotech developing spherical nucleic acid-based drugs for the treatment of neurological diseases. This chart shows the profitability of its segment. The company's R&D costs impact its current overall profitability, but its breakthrough technology could create an entirely new platform for drug delivery to hard-to-reach tissues.
Overall market profit
Exicure, Inc. is an early-stage biotech company developing therapeutics based on spherical nucleic acids. After a series of setbacks, the company is seeking strategic alternatives. Its future depends not on the state of the economy, but on its ability to find a partner or sell its technology. This chart illustrates the backdrop against which the company is struggling to survive.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Exicure Inc.
Exicure, Inc. is an early-stage biotechnology company developing therapeutics based on spherical nucleic acids. The future revenue projections reflected here are extremely long-term and speculative. They reflect the belief of a small number of analysts that the company's scientific platform will ultimately lead to the development of commercially successful drugs.
%20profit%20of%20the%20company%20Exicure%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Exicure-Inc.&v=1772646484684 "Graph of future (projected) profit of the company Exicure Inc.")
Future (predicted) profit of companies in the market segment - Dna
Exicure, Inc. is an early-stage biotech company developing therapeutics based on spherical nucleic acids (SNAs). This chart shows forecasts for the DNA pharma segment. It reflects expectations for breakthrough technologies in gene therapy, where Exicure is exploring its unique platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772646484688 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Exicure, Inc. is a biotech company working with gene therapy. Their future depends on successful clinical trials and their ability to finance them. The market's overall profit forecast, reflected in the chart, influences investors' risk appetite. Economic optimism facilitates raising capital for such long-term projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772646484690 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Exicure Inc.
Exicure, Inc. is an early-stage biotech company developing therapeutics based on spherical nucleic acids. Following a restructuring and change in focus, the company has no revenue. Its valuation is based on the potential of its scientific platform, not financial performance.
P/S market segment - Dna
Exicure, Inc. is an early-stage biotech company developing spherical nucleic acid-based drugs. Following research failures, the company is undergoing a restructuring. This chart reflects market skepticism and demonstrates how undervalued its ability to generate future revenue is without successful clinical programs.
P/S of the market as a whole
Exicure is a biotech company that has experienced clinical trial setbacks and is undergoing restructuring. The company has no commercial revenue. This chart, while showing an estimate of real revenue, emphasizes that Exicure's valuation reflects only the residual value of its technologies or cash.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Exicure Inc.
Exicure, Inc. is an early-stage biotechnology company developing therapeutics based on spherical nucleic acids. Following research failures, the company is exploring strategic alternatives. This graph reflects minimum revenue expectations but includes a speculative estimate of the residual value of its technology and assets.
%20P%2FS%20Exicure%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Exicure-Inc.&v=1772646484703 "The graph of the company's future (projected) P/S Exicure Inc.")
Future (projected) P/S of the market segment - Dna
Exicure, Inc. is an early-stage biotech developing therapeutics based on spherical nucleic acids (SNAs). Following its restructuring, its future is uncertain. This chart shows how the market views its extremely uncertain future prospects. Comparisons with other DNA companies reflect the low expectations and speculative nature of the asset.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772646484706 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Exicure is a biotech company that has faced significant challenges in developing its spherical nucleic acid-based drugs. This graph reflects general expectations for future sales, and XCUR exemplifies the high-risk nature of biotech, where clinical trial setbacks can dramatically alter the company's fortunes and investor expectations.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772646484707 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Exicure Inc.
Exicure, Inc. is an early-stage biotechnology company developing therapeutics based on spherical nucleic acids. Following a restructuring and program suspension, its operations have been reduced to a minimum. Revenue is likely absent from this chart, reflecting the company's current status.
Sales of companies in the market segment - Dna
Exicure is an early-stage biotech company developing nucleic acid-based drugs. At this stage, it likely has no revenue from product sales. The graph may reflect revenue from partnerships, which are a key source of funding for its research.
Overall market sales
Exicure, Inc. is an early-stage biotech company developing nucleic acid-based therapeutics. Its value is almost entirely dependent on the potential of its scientific platform and progress in preclinical studies. This market performance chart bears absolutely no relation to the factors that determine Exicure's success or failure.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Exicure Inc.
Exicure is an early-stage biotech company developing therapeutics based on spherical nucleic acids. Its revenue forecast reflects speculative expectations regarding the potential for a revival of its scientific platform or partnerships following its restructuring and downsizing.
%20sales%20of%20the%20company%20Exicure%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Exicure-Inc.&v=1772646484720 "Schedule of future (projected) sales of the company Exicure Inc.")
Future (projected) sales of companies in the market segment - Dna
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics based on spherical nucleic acids (SNAs). This chart shows projected revenue for the gene therapy segment. It reflects the expected growth of the precision medicine market, which is key to the commercialization of Exicure's advanced platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772646484725 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Exicure is a biotechnology company developing drugs based on spherical nucleic acids. Following research failures, the company is seeking strategic alternatives. This graph of overall market expectations is impacting the investment climate. A positive environment may facilitate the company's search for a merger partner or the sale of its remaining assets and technologies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772646484728 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Exicure Inc.
Exicure, Inc. is an early-stage biotech company developing therapeutics based on spherical nucleic acids. This chart reflects its current research focus. It doesn't show profit, but rather the effectiveness of capital management invested in the development of a new technology platform.
Market segment marginality - Dna
Exicure, Inc. is an early-stage biotechnology company developing a new class of nucleic acid-based immunomodulatory therapies. This chart reflects the average profitability in the gene therapy sector. It serves as a benchmark for assessing the potential profitability of Exicure's platform if its drugs prove effective and safe in clinical trials.
Market marginality as a whole
Exicure, Inc. is an early-stage biotech company developing a gene therapy platform. Its history is full of ups and downs. This graph of average market returns depicts a predictable world, while Exicure lives in a world of binary outcomes, where unsuccessful clinical trials can wipe out the company's value.
Employees in the company, segment and market as a whole
Number of employees in the company Exicure Inc.
Exicure was a biotech company developing spherical nucleic acid-based drugs. The sharp reduction or minimal team size in this chart likely reflects the discontinuation of key clinical programs and a major business restructuring following disappointing research results.
Share of the company's employees Exicure Inc. within the market segment - Dna
Exicure, Inc. is an early-stage biotechnology company developing a new class of therapeutics based on spherical nucleic acids (SNAs). This chart highlights its cutting-edge scientific focus. It reflects the proportion of chemists, biologists, and researchers working on this breakthrough gene therapy platform that Exicure brings together under its umbrella.
Number of employees in the market segment - Dna
Exicure, Inc. is a biotechnology company developing therapeutics based on spherical nucleic acids (SNAs). This chart shows employment in the DNA research sector. The growing number of geneticists in this cutting-edge field reflects breakthroughs in gene therapy and the search for new treatments for genetically determined diseases.
Number of employees in the market as a whole
Exicure, Inc. is an early-stage biotech company focused on gene therapy using spherical nucleic acids. It's at the cutting edge of science. This chart illustrates the overall employment landscape, where these pioneering companies, though small, are laying the foundation for future technological revolutions in medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Exicure Inc. (XCUR)
Exicure, Inc. is an early-stage biotech company. Its market capitalization is a bet on the success of its scientific platform. This chart shows the "option value" of the technology per employee. Investors are paying for the potential that can be realized by a small team of scientists.
%20of%20the%20company%20Exicure%20Inc.%20(XCUR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Exicure-Inc.-XCUR&v=1772646484769 "Chart of market capitalization per employee (in thousands of dollars) of the company Exicure Inc. (XCUR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Exicure develops therapeutics based on spherical nucleic acids (SNA), a cutting-edge field in gene therapy. Its market capitalization per employee reflects investors' faith in the revolutionary potential of its technology platform. Its very high market capitalization indicates high expectations for future clinical results.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772646484775 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Exicure is an early-stage biotech developing therapeutics based on spherical nucleic acids. After research setbacks, the company is seeking a new path. This chart reflects a low valuation, showing how the market values a company whose scientific potential has yet to meet investor expectations.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772646484781 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Exicure Inc. (XCUR)
Exicure is a biotech company developing a DNA-based drug delivery platform (SNA). The company has suffered setbacks and is in crisis. This chart, deeply negative, shows how much capital is being burned on the remaining staff in attempts to save the technology or the company.
%20Chart%20Exicure%20Inc.%20(XCUR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Exicure-Inc.-XCUR&v=1772646484792 "Company Profit Per Employee (in thousands of dollars) Chart Exicure Inc. (XCUR)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Exicure, Inc. is an early-stage biotech company developing spherical nucleic acid (SNA)-based drugs for the treatment of neurological disorders. This chart illustrates the potential value of their platform. It shows the enormous value that a breakthrough technology developed by a small team of scientists could generate if it proves effective.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772646484797 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Exicure, Inc., a biotech company developing a "spherical nucleic acid" (SNA) platform for gene therapy, faced difficulties and scaled back operations. This chart likely shows deeply negative values, reflecting the costs of scaling back R&D programs based on the remaining minimal staff.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772646484804 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Exicure Inc. (XCUR)
Exicure, Inc. is an early-stage biotech company. At this stage of research, this graph does not reflect commercial activity, as there is no revenue. It represents scientific potential. Success in development and subsequent licensing or sale of the technology will lead to a sharp increase in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Exicure-Inc.-XCUR&v=1772646484822 "Sales chart per company employee Exicure Inc. (XCUR)")
Sales per employee in the market segment - Dna
Exicure (XCUR) is a biotech company developing spherical nucleic acid (SNA)-based drugs. The company is currently undergoing a restructuring. This chart shows the average revenue per employee in the pharmaceutical segment. Comparing XCUR to this benchmark (zero) reflects its current state, where scientific activity has virtually ceased and productivity is nonexistent.
Sales per employee for the market as a whole
Exicure (XCUR) is a clinical-stage biotech company (gene therapy). The company is currently in dire straits, having cut back on R&D. This figure is close to zero. It doesn't reflect future prospects, but rather a scaling back of operations, with no revenue and the remaining staff struggling to keep the company going.
Short shares by company, segment and market as a whole
Shares shorted by company Exicure Inc. (XCUR)
Exicure, Inc. is a biotech company whose RNA therapy platform has found itself at the center of a data falsification scandal. The company has laid off staff and is seeking "strategic alternatives." This chart shows bets on "zero." Bears are convinced it's a "dead man walking," with no technology or future, and whose shares will ultimately be worth nothing.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Exicure-Inc.-XCUR&v=1772646484849 "Short Shares Chart for the Company Exicure Inc. (XCUR)")
Shares shorted by market segment - Dna
Exicure (XCUR) is a biotech whose "revolutionary" technology (SNA) has already failed. The company halted trials and laid off most of its team. This chart highlights the pessimism in the sector. The surge in shorts across the industry is a bet that the company has nothing of value left. Investors don't believe in a "reincarnation" and expect XCUR's remaining assets to be sold off for next to nothing and the company to go bankrupt.
Shares shorted by the overall market
Exicure (XCUR) is a clinical-stage biotech company working with DNA. Its value reflects its hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, requiring refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Exicure Inc. (XCUR)
Exicure develops cutting-edge drugs based on spherical nucleic acids (SNAs). This is fundamental science with a binary outcome: either breakthrough or failure. This indicator visualizes these extremes. It shows how any positive news about the technology can trigger a frenzy among investors, overheating the stock, followed by a long period of cooling off.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Exicure-Inc.-XCUR&v=1772646484868 "RSI 14 indicator chart for the company's stock Exicure Inc. (XCUR)")
RSI 14 Market Segment - Dna
Exicure is a biotech company developing a "spherical nucleic acid" (SNA) platform for gene therapy delivery. Despite early promise, the company has encountered setbacks. This chart reflects the overall sentiment in the genetic engineering sector. It helps assess whether this futuristic biotech segment is oversold or overheated.
RSI 14 for the overall market
Exicure (XCUR) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XCUR (Exicure Inc.)
Exicure is a clinical-stage biotech whose R&D platform was based on spherical nucleic acids (SNAs). Following setbacks, the company is seeking strategic alternatives. This chart shows the speculative average 12-month target price from analysts, reflecting their view on residual value.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XCUR-Exicure-Inc.&v=1772646484879 "A chart showing analyst consensus forecasts for the expected stock price. XCUR (Exicure Inc.)")
The difference between the consensus estimate and the actual stock price XCUR (Exicure Inc.)
Exicure is a biotech company developing a "spherical nucleic acid" (SNA) platform for gene therapy delivery. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their view on the value of assets and technologies after the restructuring.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XCUR-Exicure-Inc.&v=1772646484887 "A chart showing the difference between the consensus forecast and the actual stock price. XCUR (Exicure Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Exicure is a biotech company that failed with its spherical DNA (SNA) R&D platform. This chart shows analysts' overall expectations for the DNA technology sector. It reflects whether experts believe in the R&D sector as a whole or believe the industry is overrun with failed startups.
Analysts' consensus forecast for the overall market share price
Exicure was a biotech company developing a spherical nucleic acid (SNA) platform for gene therapy. (Note: the company failed and is shutting down.) This chart shows the overall "risk appetite" in the market. For Exicure, a company whose technology failed to live up to expectations, overall market optimism was no longer helpful, as it was powerless against dismal clinical data.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Exicure Inc.
Exicure is a fallen angel of R&D. They pioneered spherical nucleic acids (SNA), a new form of DNA/RNA therapeutics. After their R&D failed, the company essentially became a shell. This chart is a summary indicator of their survival, reflecting their remaining cash and the market's desperate (and unlikely) attempts to find residual value in their technology.
AKIMA Market Segment Index - Dna
Exicure (XCUR) is a biotech company developing drugs based on its spherical nucleic acid (SNA) platform, targeting neuroscience and oncology. The chart shows the segment average, helping investors assess how this struggling company stacks up against the average in the genetic engineering sector.
The AKIM Index for the overall market
Exicure is a biotech company developing spherical nucleic acids (SNA). It has undergone a restructuring and strategic shift. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this troubled microcap story fits in with overall economic trends and the search for strategic alternatives.
